The evolution of resistant Candida species in cancer centers: Implications for treatment and prophylaxis

Cancer

Volumn 112, Issue 11, 2008, Pages 2334-2337

  Riddell IV, James ^a   Kauffman, Carol A ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ECHINOCANDIN; FLUCONAZOLE; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

CANCER CENTER; CANDIDA; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDEMIA; CANDIDIASIS; EDITORIAL; EVOLUTION; HIGH RISK POPULATION; HUMAN; MORBIDITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SPECIES; TERTIARY HEALTH CARE; ANTIFUNGAL RESISTANCE; CLASSIFICATION; MICROBIOLOGY; NEOPLASM; NOTE; PATHOGENICITY;

ANTIFUNGAL AGENTS; CANCER CARE FACILITIES; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; HUMANS; NEOPLASMS;

EID: 52049089240     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23465     Document Type: Editorial

References (23)

1. Trick W, Fridkin S, Edwards J, Hajjeh R, Gaynes R. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis. 2002;35:622-630.
2. Wisplinghoff H, Bischoff T, Tallent S, Seifert H, Wenzel R, Edmond M. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309-317.
3. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Contr. 1999; 27:520-532.
4. Wenzel R, Edmond M. The impact of hospital-acquired bloodstream infections. Emerg Infect Dis. 2001;7:174-177.
5. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003; 37:1172-1177.
6. Hachem R, Hanna J, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer. 2008;112:2493-2499.
7. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis. 1997;24:1122-1128.
8. Pfaller M, Diekema D. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20:133-163.
9. Pfaller M, Diekema D, Rinaldi M, et al. Results from the ARTEMIS DISK global antifungal surveillance study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol. 2005;43:5848-5859.
10. Marr K, Seidel K, White T, Bowden R. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis. 2000;181:309-316.
11. Lin M, Carmeli Y, Zumsteg J, et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agent Chemother. 2005;49:4555-4560.
12. Malani A, Hmoud J, Chiu L, Carver P, Bielaczyc A, Kauffman C. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis. 2005;41:975-981.
13. Diekema D, Messer S, Brueggemann A, et al. Epidemiology of candidemia: three-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol. 2002;40:1298-1302.
14. Reboli A, Rotstein C, Pappas P, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356:2472-2482.
15. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020-2029.
16. Pappas P, Rex J, Sobel J, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38:161-189.
17. Magill S, Shields C, Sears C, Choti M, Merz W. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol. 2006;44:529-535.
18. Panackal A, Gribskov J, Staab J, Kirby K, Rinaldi M, Marr K. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol. 2006;44:1740-1743.
19. Cornely O, Maertens J, Winston D, et al. Posaconazole versus fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348-359.
20. Ullmann A, Lipton J, Vesole D, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335-347.
21. Wingard J, Carter S, Walsh T, et al. Results of a randomized, double-blind trial of fluconazole versus voriconazole for the prevention of invasive fungal infections in 600 allogeneic blood and marrow transplant patients [abstract]. Blood. 2007;110. Abstract 163.
22. Garey K, Rege M, Pai M, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25-31.
23. Morrell M, Fraser V, Kollef M. Delaying empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for mortality. Antimicrob Agent Chemother. 2005;49:3640-3645.